ESRD may disrupt the biomechanical properties of the cornea. Changes in ocular response analyzer parameters should be kept in mind to evaluate accurate IOP measurements in patients with ESRD.

A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : To investigate the outcomes of phacoemulsification and posterior intraocular lens implantation (IOL) in patients with chronic or recurrent uveitis. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : The records of 84 patients, who had phacoemulsification and IOL implantation between 2010 and 2015, were retrospectively examined. The main outcomes were final visual acuity, postoperative complications, the presence of relapse, the clinical features of patients who suffered a recurrence of intraocular inflammation and the effect of triamcinolone acetonide injection into the anterior chamber during surgery on the recurrence of inflammation after cataract surgery within the first 6 months. R Re es su ul lt ts s: : The study included 109 eyes of 84 patients. The mean follow-up time was 52.6±41.8 (9-224) months. During the follow-up, posterior capsule opacification occurred in 48 (44.0%), deposits on the IOL surface in 19 (17.4%), posterior synechiae in 2 (1.8%), epiretinal membrane in 4 (3.6%), glaucoma in 7 (6.4%), and macular edema in 5 (4.5%) patients. The best corrected visual acuity with the Snellen chart at the final visit was ≤0.16 in 66.7% of serpiginous choroidopathy patients and 38% of Behçet patients. These rates were higher than with other clinical etiologies. Recurrence of uveitis within 6 months after cataract surgery occurred in 15 (13.7%) eyes. Recurrence was most common in patients with Behcet's disease. Pre-existing macular lesions were accompanied by poor visual outcomes. There was no difference between the eyes administered triamcinolone into the anterior chamber or not, regarding the frequency of attacks within the first 6 months or the postoperative complications. C Co on nc cl lu us si io on n: : Cataract surgery outcomes in patients with uveitis are satisfactory. However, patients with Behcet's disease have higher risk for relapse of intraocular inflammation and worse visual outcomes. K Ke ey yw wo or rd ds s: : Cataract; triamcinolone; uveitis; visual acuity Ö ÖZ ZE ET T A Am ma aç ç: : Kronik veya tekrarlayan üveitik hastalarda fakoemülsifikasyon ve arka kamara göz içi lensi (GİL) yerleştirilen hastaların sonuçlarını değerlendirmek. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : 2010 ila 2015 yılları arasında fakoemülsifikasyon ve arka kamara GİL'i yerleştirilen 84 hastanın kayıtları geriye dönük olarak incelendi. Sonuçların değerlendirilmesinde, sonuç görme keskinliği, cerrahi sonrası komplikasyonlar, atak varlığı, cerrahiyi takiben ilk 6 ay içerisinde atak geçiren hastaların özellik-leri ve cerrahi esnasında ön kamaraya triamsinolon verilen hastalarda inflamasyon aktivitesi üze-rine olan etkisi değerlendirildi. B Bu ul lg gu ul la ar r: : Çalışma, 84 hastanın 109 gözünü kapsamaktaydı. Ortalama takip süresi 52,6±41,8 (9-224) ay idi. Takip süresi boyunca, arka kapsül kesafeti 48 (%44,0), GİL'nin ön yüzeyinde birikim 19 (%17,4), arka sineşiler 2 (%1,8), epiretinal membran 4 (%3,6), glokom 7 (%6,4) ve maküler ödem 5 (%4,5) ...

Aims: To investigate the changes in vision-related quality of life after a loading dose of three consecutive intravitreal ranibizumab (IVR) injections in patients with unilateral diabetic macular edema (DME). Materials and Methods: Fifty-two eyes of 52 patients who received IVR injections in only one eye with DME were included in our study. The following characteristics of the patients were recorded: gender, education status, marital status, work status, presence of chronic disease. The changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated at baseline (before treatment) and 1 month after the third intravitreal injection (after treatment). Patients were administered the Turkish form of the National Eye Institute 25-Item Visual Functions Questionnaire (NEI VFQ-25 TR). The quality of life scores assessed by the NEI VFQ-25 TR, the BCVA, intraocular pressure (IOP), and CMT measurements were compared at baseline (before treatment) and 1 month after the third intravitreal injection (after treatment). Results: We enrolled 52 patients (25 females, 27 males) in our study; mean age was 64.35 ± 9.26 years. After treatment, BCVA improved significantly (p = 0.001), and macular thickness decreased significantly (p < 0.001). All NEI VFQ-25 TR subscale scores were significantly higher after treatment (p < 0.05). However, no significant correlation was found between the change in BCVA and CMT and the change in NEI VFQ-25 TR subscale and composite scores. The increase in near activities scores was significantly higher in males (p = 0.020) and in the retired group (p = 0.022). There were no significant differences in the changes in NEI VFQ-25 TR subscale and composite scores in relation to educational status. Discussion: Significant improvements in BCVA, macular edema, and vision-related quality of life were found in DME patients who received IVR injections with a loading dose, as shown by the NEI VFQ-25 TR. Interestingly, a significant improvement in quality of life was observed even though the patients could see well with the fellow eye. In conclusion, the NEI VFQ-25 TR is a useful scale to evaluate the changes in visual function and psychosocial characteristics of DME patients after treatment.

When the measurement and refractive results of the OLCR biometry were evaluated, it was observed that there was a very satisfactory result and a predictable device compatible with the current literature. The SRK/T formula, one of the new generation formulas, has shown high MAE and RE results in eyes with AL ≤ 22 mm, although not statistically significant. Other new generation formulas should be tried in these eyes.